Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-06-14-Speech-4-335-750"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120614.22.4-335-750"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"It is regrettable that there is no clinical or epidemiological data available about the potential risks of PIP breast implants. In addition, random checks on PIP silicone implants have shown that the outer membrane manufactured by PIP has weaknesses that do not occur in other commercially available implants. This is dangerous for women because many PIP implants are made from non-medical grade silicone that contains constituents that attack the outer membrane of the implant and then enter the body’s tissue cells. Some Member States have advised women who have had such implants inserted to consult with their surgeons or to have the PIP implants removed as a precautionary measure. For this reason, it is necessary to set down the immediate introduction and implementation of fundamental, targeted direct measures according to the current legal provisions for medical products. It would make sense to carry out thorough spot checks on medical products that represent the highest risk, so that such situations can be prevented. The Commission should require suitable toxicological assessment for all medical products, and should propose that all carcinogenic, mutagenic or reprotoxic substances should be gradually removed from the market. It would be a good idea for the Member States to impose sanctions for noncompliance with the new laws. These are some of the reasons why I voted in favour of this motion."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples